Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14906625 | 0.86 | TLR9 (0.58) | TLR9PDGFRBPDGFRAKMT2AATM | |
| SCHEMBL28191718 | 0.83 | ESR2 (0.59) | PDGFRBPDGFRABACE1ESR2CYP2A6 | |
| SCHEMBL19943005 | 0.80 | PDGFRB (0.66) | PDGFRBPDGFRAKMT2AATMHTR3A | |
| SCHEMBL30722842 | 0.80 | PDGFRB (0.66) | PDGFRBPDGFRAKMT2AATMHTR3A | |
| SCHEMBL21630183 | 0.79 | CTSD (0.56) | TLR9PDGFRBPDGFRAKMT2AATM | |
| SCHEMBL708999 | 0.79 | PDGFRB (0.75) | PDGFRBPDGFRACYP2A6CA12CA1 | |
| SCHEMBL5667402 | 0.79 | PDGFRB (0.73) | PDGFRBPDGFRAESR2ADORA3CYP2A6 | |
| SCHEMBL20759765 | 0.79 | PSMB5 (0.63) | PDGFRBPDGFRAESR2ADORA3CYP2A6 | |
| SCHEMBL30644240 | 0.79 | PDGFRB (0.73) | PDGFRBPDGFRAESR2ADORA3CYP2A6 | |
| SCHEMBL26560544 | 0.79 | PDGFRB (0.64) | PDGFRBPDGFRABACE1ESR2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555026-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| CN-109776335-B | Amine derivative of pyrene, preparation method, application and device thereof | 武汉尚赛光电科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-10696650-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696650-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3668496-A1 | AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| CN-111163766-A | AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-109776335-A | Amine derivant of pyrene and preparation method thereof, application and device | 武汉尚赛光电科技有限公司 | 2019-05-21 | — | — | CN | disclosed |
| US-20190055218-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20190055218-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2019036657-A1 | AHR INHIBITORS AND USES THEREOF | KYN THERAPEUTICS (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036657-A1 | AHR INHIBITORS AND USES THEREOF | KYN THERAPEUTICS (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555026-B2 | AHR inhibitors and uses thereof | AHR, ARNT, AIPL1 | TLR9 865/4885PDGFRB 937/4885PDGFRA 1392/4885 |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | AHR, ARNT, AIPL1 | TLR9 865/4885PDGFRB 937/4885PDGFRA 1392/4885 |
| US-10696650-B2 | AHR inhibitors and uses thereof | AHR, ARNT, AIPL1 | TLR9 865/4885PDGFRB 937/4885PDGFRA 1392/4885 |
| US-20190055218-A1 | AHR INHIBITORS AND USES THEREOF | AHR, ARNT, AIPL1 | TLR9 865/4885PDGFRB 937/4885PDGFRA 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.